» WHAT … are our strengths and assets?
Excellence –Professor R. Zeillinger has more than 35-years’ experience in academic and industrial research in the field of molecular oncology as well as in the management of diagnostic enterprises. In addition, he has successfully coordinated international research projects and is a distinguished author of a large number of scientific publications.
Achievements – Early detection tests have been developed for ovarian, breast and pancreatic cancer, displaying unprecedented sensitivity and specificity. Therapy monitoring tests have been developed for various types of cancer – in particular for breast cancer and gynaecological cancers.
Patents – Intellectual property rights forall diagnostic tests are secured.
Access to Patients & Biomaterials –Excellent access to patients, biomaterials, and clinical information through the Medical University of Vienna and other university & medical centers worldwide is a unique asset – an advantage other companies usually don’t have.
Network – International network of basic & translational scientists, clinicians, cancer centers and universities.
A step ahead –Up to date there is no diagnostic test for cancer on the market which is based on RNA expression biomarkers in immune cells. Likewise, none of the existing methods shows sufficient sensitivity and specificity for reliable test results — much less do they have a potential for screening of high-risk persons or even population-wide screening. Our proven concept with exceptional sensitivity and specificity positions us a step ahead of our competitors.